Literature DB >> 23094849

Inheritance of the chronic myeloproliferative neoplasms. A systematic review.

A Ranjan1, E Penninga, A M Jelsig, H C Hasselbalch, O W Bjerrum.   

Abstract

This systematic review investigated the inheritance of the classical chronic myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic myelogenous leukemia (CML). Sixty-one articles were included and provided 135 families with a total of 341 participants distributed to various subtypes of MPN: 50% PV, 23% ET, 14% PMF, 10% CML and 3% non-MPN hematological disorder. Women developed the disease earlier than men (43.1 years vs 47.3 years; p = 0.074), while the general average age of onset was 46 years, notably younger than sporadic cases. The clinical phenotype of the families showed a homogenous (67%) and a heterogeneous (33%) pattern, with the majority being PV-PV pairs (36%) and PV-PMF pairs (17%), respectively. This observation suggests that the susceptibility gene (or genes) is not restricted to one subtype supporting the hypothesis of a mutation in an early multipotent stem cell. Furthermore, a major subgroup of families provided evidence of an autosomal dominant (AD) inheritance with reduced penetrance. This study suggests that the origin of MPNs may occur in at least three different settings: (i) a sporadic, (ii) genetic heterogeneity with polygenetic and environmental impact and (iii) a familial phenotype following an AD inheritance.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23094849     DOI: 10.1111/cge.12044

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

Review 1.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02

2.  Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

Authors:  N Jaekel; G Behre; A Behning; C Wickenhauser; T Lange; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2013-12-02       Impact factor: 5.483

3.  Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Authors:  Samer A Srour; Susan S Devesa; Lindsay M Morton; David P Check; Rochelle E Curtis; Martha S Linet; Graça M Dores
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

4.  Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations.

Authors:  Stephen E Langabeer; Karl Haslam; Jennifer Linders; Melanie J Percy; Eibhlin Conneally; Amjad Hayat; Brian Hennessy; Maeve Leahy; Karen Murphy; Margaret Murray; Fionnuala Ni Ainle; Patrick Thornton; Jeremy Sargent
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

5.  Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer.

Authors:  Marisa J L Aitken; Christopher B Benton; Ghayas C Issa; Koji Sasaki; Musa Yilmaz; Nicholas J Short
Journal:  Acta Haematol       Date:  2021-03-18       Impact factor: 2.195

6.  Haemoglobinopathia Ypsilanti - A rare, but important differential diagnosis to polycythaemia vera.

Authors:  Marietta Nygaard; Jesper Petersen; Ole W Bjerrum
Journal:  Leuk Res Rep       Date:  2013-10-09

7.  The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.

Authors:  Yan Chen; Fang Fang; Yang Hu; Qian Liu; Dingfang Bu; Mei Tan; Liusong Wu; Ping Zhu
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

8.  B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib.

Authors:  Krzysztof Lewandowski; Michał Gniot; Maria Lewandowska; Anna Wache; Błażej Ratajczak; Anna Czyż; Małgorzata Jarmuż-Szymczak; Mieczysław Komarnicki
Journal:  Case Rep Med       Date:  2016-03-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.